title: In vivo reprogramming for heart disease.
abstract: The term "lineage reprogramming" is typically used to describe the conversion of one differentiated somatic cell type into another without transit through a pluripotent intermediate. Two recent reports in Nature demonstrate that such a conversion can be achieved in the heart in situ, and suggest a novel, regenerative approach for the development of cardiac therapeutics.
authors: 1] Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, MA 02138, USA.
authors: Huansheng
authors: H
authors: Xu
authors: B Alexander
authors: BA
authors: Yi
authors: Kenneth R
authors: KR
authors: Chien
mesh_terms: D002454:Cell Differentiation; D019070:Cell Lineage; D054338:Cell Transdifferentiation; D065150:Cellular Reprogramming; D005347:Fibroblasts / Q000166:cytology* / Q000502:physiology; D006321:Heart / Q000502:physiology*; D006333:Heart Failure / Q000628:therapy*; D006801:Humans; D017570:MyoD Protein / Q000096:biosynthesis; D032383:Myocytes, Cardiac / Q000166:cytology* / Q000502:physiology; D012038:Regeneration; D044968:Regenerative Medicine / Q000379:methods
chemical_list: D017570:MyoD Protein; C057363:MyoD1 myogenic differentiation protein